Neuphoria Therapeutics (NEUP) provided a review of 2024 and highlighted plans for 2025. “2024 and the first quarter of 2025 were transformational for our pipeline; Our internal BNC210 program ...

Ulz covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Viking Therapeutics. In addition to Morgan Stanley, Sarepta Therapeutics also received a Buy ...

March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the ... together with IDEA Pharma, a Division of SAI MedPartners (IDEA), a pioneering biopharmaceutical strategy consultancy ...

In December 2023, Sun Pharma had invested in Lyndra Therapeutics Inc – agreeing to acquire about 16.7 percent in Lyndra Therapeutics, engaged in developing novel delivery technology for long ...

(RTTNews) - NRx Pharmaceuticals, Inc. (NRXP) announced Monday that its interventional psychiatry network HOPE Therapeutics, Inc. has signed a definitive agreement to acquire Dura Medical following ...

Alizé Pharma, acquired by Millendo Therapeutics (2017); Alizé Pharma 2, acquired by Jazz Pharmaceuticals (2016); and Amolyt Pharma, acquired by AstraZeneca (2024). Prior to his entrepreneurial ...

Under the agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics for RAF/RAS-mutant solid tumors. Under the terms of the deal ...

Plus Therapeutics shares are trading higher by ... The company says it aims to build awareness of the REYOBIQ name and logo, reinforcing its progress in developing targeted radiotherapeutics ...

Alizé Pharma, acquired by Millendo Therapeutics (2017); Alizé Pharma 2, acquired by Jazz Pharmaceuticals (2016); and Amolyt Pharma, acquired by AstraZeneca (2024). Prior to his entrepreneurial track, ...

A source familiar with the situation told the Business Journal that the executive team and board of directors at Lyndra Therapeutics resigned on Tuesday. Lyndra Therapeutics, a drug developer that ...

Purdue Pharma has filed a new bankruptcy plan as part of a $7.4 billion settlement to resolve thousands of lawsuits over the company’s alleged role in the opioid crisis, months after the Supreme ...

The Motley Fool has positions in and recommends Amgen, Axsome Therapeutics, Merck, and Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy.